V6758
VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human
>90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder
Synonym(s):
Vascular Endothelial Growth Factor Receptor‑2
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
human
Quality Level
recombinant
expressed in NSO cells
Assay
>90% (SDS-PAGE)
form
lyophilized powder
potency
10-40 ng/mL ED50
mol wt
predicted mol wt ~110 kDa
packaging
pkg of 50 μg
storage condition
avoid repeated freeze/thaw cycles
impurities
endotoxin, tested
UniProt accession no.
storage temp.
−20°C
Gene Information
human ... KDR(3791)
Application
VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human is a homodimeric protein contains extracellular domain of human VEGF R2 (KDR) fused to the 6x histidine tagged Fc portion of human IgG1 by the peptide (EGF). The product was used to stuyd vasculogenesis and angiogenesis and as marker for pluripotent hematopoietic stem cells.
Biochem/physiol Actions
VEGF Receptor-2 (VEGF R2) also known as Flk-1 or KDR belongs to class III subfamily of RTKs is a potent VEGF antagonist and is mainly expressed in endothelial cells. VEGF R2 can stimulate PLC-gamma pathway which in turn activate MAP kinase and subsequent strong signalling as well as can partly induces mitotic signals in NIH3T3 fibroblasts. KDR also facilitates the release of nitric oxide in endothelial cells and assist in the regulation of the vasculature.
VEGF receptors, class III receptor tyrosine kinases, have seven Ig like extracellular motifs and a tyrosine kinase intracellular domain split by a kinase insert sequence. VEGFR 1 and 2 are both expressed in an endothelial cell-specific manner.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 2.5 mg bovine serum albumin.
Analysis Note
The biological activity is measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
B L Ziegler et al.
Science (New York, N.Y.), 285(5433), 1553-1558 (1999-09-08)
Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial
J Kroll et al.
Biochemical and biophysical research communications, 265(3), 636-639 (1999-12-22)
VEGF-A induces angiogenesis and regulates endothelial function via production and release of nitric oxide (NO), which is produced by endothelial nitric oxide synthase (eNOS). While the upregulation of eNOS expression has been shown to be mediated via VEGF receptor KDR
T Takahashi et al.
Oncogene, 14(17), 2079-2089 (1997-05-01)
KDR/Flk-1 tyrosine kinase, one of the two receptors for Vascular Endothelial Growth Factor (VEGF) has been shown to generate the major part of mitotic signals in endothelial cells, although the mechanisms are poorly understood. Here we examined the processing and
Yanelys Morera et al.
Vaccine, 35(28), 3582-3590 (2017-05-26)
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service